tiprankstipranks
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
US Market
JAZZ
Jazz Pharmaceuticals
RESEARCH TOOLSreports
Want to see JAZZ full AI Analyst Report?

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

1,877 Followers
See the Price Targets and Ratings of:

JAZZ Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JAZZ Stock 12 Month Forecast

Average Price Target

$230.50
▲(13.31% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $230.50 with a high forecast of $275.00 and a low forecast of $195.00. The average price target represents a 13.31% change from the last price of $203.42.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"107":"$107","276":"$276","149.25":"$149.3","191.5":"$191.5","233.75":"$233.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$275.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$230.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":195,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$195.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[107,149.25,191.5,233.75,276],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,188.27,194.94153846153847,201.61307692307693,208.2846153846154,214.95615384615385,221.6276923076923,228.29923076923077,234.97076923076924,241.6423076923077,248.31384615384616,254.98538461538462,261.6569230769231,268.3284615384615,{"y":275,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,188.27,191.51846153846154,194.7669230769231,198.01538461538462,201.26384615384617,204.5123076923077,207.76076923076923,211.00923076923078,214.2576923076923,217.50615384615384,220.7546153846154,224.00307692307692,227.25153846153847,{"y":230.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,188.27,188.7876923076923,189.3053846153846,189.82307692307694,190.34076923076924,190.85846153846154,191.37615384615384,191.89384615384617,192.41153846153847,192.92923076923077,193.44692307692307,193.9646153846154,194.4823076923077,{"y":195,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":124.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$275.00Average Price Target$230.50Lowest Price Target$195.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on JAZZ
Etzer Darout
Barclays
Barclays
$224→$225
Buy
10.61%
Upside
Assigned
04/20/26
Jazz Pharmaceuticals price target raised to $225 from $224 at BarclaysJazz Pharmaceuticals price target raised to $225 from $224 at Barclays
Needham Analyst forecast on JAZZ
Ami Fadia
Needham
Needham
$235
Buy
15.52%
Upside
Assigned
04/16/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), KalVista Pharmaceuticals (NASDAQ: KALV) and TScan Therapeutics (NASDAQ: TCRX)
Raymond James Analyst forecast on JAZZ
Tiago Fauth
Raymond James
Raymond James
$227
Buy
11.59%
Upside
Initiated
04/10/26
Jazz Pharmaceuticals resumed with an Outperform at Raymond JamesJazz Pharmaceuticals resumed with an Outperform at Raymond James
Wells Fargo Analyst forecast on JAZZ
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
22.90%
Upside
Reiterated
04/09/26
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Wells Fargo
RBC Capital Analyst forecast on JAZZ
Leonid Timashev
RBC Capital
RBC Capital
$195
Buy
-4.14%
Downside
Reiterated
04/06/26
RBC Capital Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Piper Sandler Analyst forecast on JAZZ
David Amsellem
Piper Sandler
Piper Sandler
$219→$232
Buy
14.05%
Upside
Reiterated
03/19/26
Piper Sandler Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Morgan Stanley Analyst forecast on JAZZ
Sean Laaman
Morgan Stanley
Morgan Stanley
$226
Buy
11.10%
Upside
Reiterated
03/09/26
Analysts Are Bullish on These Healthcare Stocks: Rapport Therapeutics, Inc. (RAPP), Jazz Pharmaceuticals (JAZZ)
Deutsche Bank Analyst forecast on JAZZ
David Hoang
Deutsche Bank
Deutsche Bank
$225→$226
Buy
11.10%
Upside
Reiterated
03/05/26
Jazz Pharmaceuticals price target raised to $226 from $225 at Deutsche BankJazz Pharmaceuticals price target raised to $226 from $225 at Deutsche Bank
Jefferies Analyst forecast on JAZZ
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$225
Buy
10.61%
Upside
Reiterated
02/25/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Jefferies
Truist Financial Analyst forecast on JAZZ
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Baxter International (NYSE: BAX)
Bank of America Securities Analyst forecast on JAZZ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$263→$275
Buy
35.19%
Upside
Reiterated
02/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Stifel Nicolaus Analyst forecast on JAZZ
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$230
Buy
13.07%
Upside
Reiterated
02/25/26
Stifel Nicolaus Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TD Cowen Analyst forecast on JAZZ
Joseph Thome
TD Cowen
TD Cowen
$220
Buy
8.15%
Upside
Reiterated
02/24/26
Jazz Pharmaceuticals: Underappreciated Growth Story with Durable Sleep Franchise and Pipeline-Driven Upside
UBS Analyst forecast on JAZZ
Ashwani Verma
UBS
UBS
$188
Hold
-7.58%
Downside
Downgraded
11/24/25
Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges
Robert W. Baird Analyst forecast on JAZZ
Brian Skorney
Robert W. Baird
Robert W. Baird
$160→$209
Buy
2.74%
Upside
Reiterated
11/18/25
Jazz Pharmaceuticals price target raised to $209 from $160 at BairdJazz Pharmaceuticals price target raised to $209 from $160 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on JAZZ
Etzer Darout
Barclays
Barclays
$224→$225
Buy
10.61%
Upside
Assigned
04/20/26
Jazz Pharmaceuticals price target raised to $225 from $224 at BarclaysJazz Pharmaceuticals price target raised to $225 from $224 at Barclays
Needham Analyst forecast on JAZZ
Ami Fadia
Needham
Needham
$235
Buy
15.52%
Upside
Assigned
04/16/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), KalVista Pharmaceuticals (NASDAQ: KALV) and TScan Therapeutics (NASDAQ: TCRX)
Raymond James Analyst forecast on JAZZ
Tiago Fauth
Raymond James
Raymond James
$227
Buy
11.59%
Upside
Initiated
04/10/26
Jazz Pharmaceuticals resumed with an Outperform at Raymond JamesJazz Pharmaceuticals resumed with an Outperform at Raymond James
Wells Fargo Analyst forecast on JAZZ
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
22.90%
Upside
Reiterated
04/09/26
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Wells Fargo
RBC Capital Analyst forecast on JAZZ
Leonid Timashev
RBC Capital
RBC Capital
$195
Buy
-4.14%
Downside
Reiterated
04/06/26
RBC Capital Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Piper Sandler Analyst forecast on JAZZ
David Amsellem
Piper Sandler
Piper Sandler
$219→$232
Buy
14.05%
Upside
Reiterated
03/19/26
Piper Sandler Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Morgan Stanley Analyst forecast on JAZZ
Sean Laaman
Morgan Stanley
Morgan Stanley
$226
Buy
11.10%
Upside
Reiterated
03/09/26
Analysts Are Bullish on These Healthcare Stocks: Rapport Therapeutics, Inc. (RAPP), Jazz Pharmaceuticals (JAZZ)
Deutsche Bank Analyst forecast on JAZZ
David Hoang
Deutsche Bank
Deutsche Bank
$225→$226
Buy
11.10%
Upside
Reiterated
03/05/26
Jazz Pharmaceuticals price target raised to $226 from $225 at Deutsche BankJazz Pharmaceuticals price target raised to $226 from $225 at Deutsche Bank
Jefferies Analyst forecast on JAZZ
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$225
Buy
10.61%
Upside
Reiterated
02/25/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Jefferies
Truist Financial Analyst forecast on JAZZ
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Baxter International (NYSE: BAX)
Bank of America Securities Analyst forecast on JAZZ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$263→$275
Buy
35.19%
Upside
Reiterated
02/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Stifel Nicolaus Analyst forecast on JAZZ
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$230
Buy
13.07%
Upside
Reiterated
02/25/26
Stifel Nicolaus Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TD Cowen Analyst forecast on JAZZ
Joseph Thome
TD Cowen
TD Cowen
$220
Buy
8.15%
Upside
Reiterated
02/24/26
Jazz Pharmaceuticals: Underappreciated Growth Story with Durable Sleep Franchise and Pipeline-Driven Upside
UBS Analyst forecast on JAZZ
Ashwani Verma
UBS
UBS
$188
Hold
-7.58%
Downside
Downgraded
11/24/25
Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges
Robert W. Baird Analyst forecast on JAZZ
Brian Skorney
Robert W. Baird
Robert W. Baird
$160→$209
Buy
2.74%
Upside
Reiterated
11/18/25
Jazz Pharmaceuticals price target raised to $209 from $160 at BairdJazz Pharmaceuticals price target raised to $209 from $160 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

3 Months
xxx
Success Rate
14/21 ratings generated profit
67%
Average Return
+3.40%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.40% per trade.
1 Year
Joon LeeTruist Financial
Success Rate
18/21 ratings generated profit
86%
Average Return
+26.43%
Copying Joon Lee's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +26.43% per trade.
2 Years
xxx
Success Rate
19/21 ratings generated profit
90%
Average Return
+49.56%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 90.48% of your transactions generating a profit, with an average return of +49.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZ Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
9
7
2
2
0
Buy
20
24
24
27
21
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
32
26
29
21
In the current month, JAZZ has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is 230.50.
Each month's total comprises the sum of three months' worth of ratings.

JAZZ Financial Forecast

JAZZ Earnings Forecast

Next quarter’s earnings estimate for JAZZ is $4.71 with a range of $3.75 to $5.62. The previous quarter’s EPS was $6.64. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.
Next quarter’s earnings estimate for JAZZ is $4.71 with a range of $3.75 to $5.62. The previous quarter’s EPS was $6.64. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Sales Forecast

Next quarter’s sales forecast for JAZZ is $981.78M with a range of $914.00M to $1.06B. The previous quarter’s sales results were $1.20B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.
Next quarter’s sales forecast for JAZZ is $981.78M with a range of $914.00M to $1.06B. The previous quarter’s sales results were $1.20B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 230.50.
    What is JAZZ’s upside potential, based on the analysts’ average price target?
    Jazz Pharmaceuticals has 13.31% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JAZZ a Buy, Sell or Hold?
          Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Jazz Pharmaceuticals’s price target?
            The average price target for Jazz Pharmaceuticals is 230.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $275.00 ,the lowest forecast is $195.00. The average price target represents 13.31% Increase from the current price of $203.42.
              What do analysts say about Jazz Pharmaceuticals?
              Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of JAZZ?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.